Chronic Lymphocytic Leukemia Clinical Trial
— GENUINEOfficial title:
A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
| Verified date | April 2022 |
| Source | TG Therapeutics, Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This study evaluates the effect of the addition of ublituximab, a novel monoclonal antibody, to ibrutinib compared to ibrutinib alone on antitumor activity, as measured by the overall response rate (ORR = CR [complete response] + PR [partial response]) in previously treated Chronic Lymphocytic Leukemia (CLL) participants with high-risk cytogenetic features. Half of the participants will receive ublituximab in combination with ibrutinib, while the other half will receive ibrutinib alone.
| Status | Completed |
| Enrollment | 126 |
| Est. completion date | April 1, 2020 |
| Est. primary completion date | April 1, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment - At least one high-risk cytogenetic feature defined by the presence of 17p deletion, 11q deletion and/or p53 mutation - Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 Exclusion Criteria: - Any major surgery, chemotherapy or immunotherapy within the last 21 days - Evidence of hepatitis B virus, hepatitis C virus or known human immunodeficiency virus (HIV) infection - Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded - Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation) - Previous therapy with ibrutinib, or any drug that specifically inhibits Bruton's tyrosine kinase (BTK) |
| Country | Name | City | State |
|---|---|---|---|
| Israel | TG Therapeutics Investigational Trial Site | Ashkelon | |
| United States | TG Therapeutics Investigational Trial Site | Albany | Georgia |
| United States | TG Therapeutics Investigational Trial Site | Ames | Iowa |
| United States | TG Therapeutics Investigational Trial Site | Aurora | Colorado |
| United States | TG Therapeutics Investigational Trial Site | Austin | Texas |
| United States | TG Therapeutics Investigational Trial Site | Baltimore | Maryland |
| United States | TG Therapeutics Investigational Trial Site | Baltimore | Maryland |
| United States | TG Therapeutics Investigational Trial Site | Baton Rouge | Louisiana |
| United States | TG Therapeutics Investigational Trial Site | Bethesda | Maryland |
| United States | TG Therapeutics Investigational Trial Site | Blacksburg | Virginia |
| United States | TG Therapeutics Investigational Trial Site | Boca Raton | Florida |
| United States | TG Therapeutics Investigational Trial Site | Boston | Massachusetts |
| United States | TG Therapeutics Investigational Trial Site | Bridgeport | Connecticut |
| United States | TG Therapeutics Investigational Trial Site | Camp Hill | Pennsylvania |
| United States | TG Therapeutics Investigational Trial Site | Canton | Ohio |
| United States | TG Therapeutics Investigational Trial Site | Cedar Rapids | Iowa |
| United States | TG Therapeutics Investigational Trial Site | Chandler | Arizona |
| United States | TG Therapeutics Investigational Trial Site | Charlotte | North Carolina |
| United States | TG Therapeutics Investigational Trial Site | Cincinnati | Ohio |
| United States | TG Therapeutics Investigational Trial Site | Cleveland | Ohio |
| United States | TG Therapeutics Investigational Trial Site | Columbia | Maryland |
| United States | TG Therapeutics Investigational Trial Site | Coon Rapids | Minnesota |
| United States | TG Therapeutics Investigational Trial Site | Dallas | Texas |
| United States | TG Therapeutics Investigational Trial Site | Denton | Texas |
| United States | TG Therapeutics Investigational Trial Site | Detroit | Michigan |
| United States | TG Therapeutics Investigational Trial Site | Durham | North Carolina |
| United States | TG Therapeutics Investigational Trial Site | East Brunswick | New Jersey |
| United States | TG Therapeutics Investigational Trial Site | Evanston | Illinois |
| United States | TG Therapeutics Investigational Trial Site | Fayetteville | Arkansas |
| United States | TG Therapeutics Investigational Trial Site | Fort Myers | Florida |
| United States | TG Therapeutics Investigational Trial Site | Fort Sam Houston | Texas |
| United States | TG Therapeutics Investigational Trial Site | Fort Wayne | Indiana |
| United States | TG Therapeutics Investigational Trial Site | Fullerton | California |
| United States | TG Therapeutics Investigational Trial Site | Greenbrae | California |
| United States | TG Therapeutics Investigational Trial Site | Greenville | South Carolina |
| United States | TG Therapeutics Investigational Trial Site | Greenville | South Carolina |
| United States | TG Therapeutics Investigational Trial Site | Howell | New Jersey |
| United States | TG Therapeutics Investigational Trial Site | Huntsville | Alabama |
| United States | TG Therapeutics Investigational Trial Site | Indianapolis | Indiana |
| United States | TG Therapeutics Investigational Trial Site | Jonesboro | Arkansas |
| United States | TG Therapeutics Investigational Trial Site | Lebanon | New Hampshire |
| United States | TG Therapeutics Investigational Trial Site | Lincoln | Nebraska |
| United States | TG Therapeutics Investigational Trial Site | Los Angeles | California |
| United States | TG Therapeutics Investigational Trial Site | Maywood | Illinois |
| United States | TG Therapeutics Investigational Trial Site | Memphis | Tennessee |
| United States | TG Therapeutics Investigational Trial Site | Mobile | Alabama |
| United States | TG Therapeutics Investigational Trial Site | Morristown | New Jersey |
| United States | TG Therapeutics Investigational Trial Site | Nashville | Tennessee |
| United States | TG Therapeutics Investigational Trial Site | New Orleans | Louisiana |
| United States | TG Therapeutics Investigational Trial Site | New York | New York |
| United States | TG Therapeutics Investigational Trial Site | Newark | Delaware |
| United States | TG Therapeutics Investigational Trial Site | Newnan | Georgia |
| United States | TG Therapeutics Investigational Trial Site | Niles | Illinois |
| United States | TG Therapeutics Investigational Trial Site | Ogden | Utah |
| United States | TG Therapeutics Investigational Trial Site | Omaha | Nebraska |
| United States | TG Therapeutics Investigational Trial Site | Orange City | Florida |
| United States | TG Therapeutics Investigational Trial Site | Pawtucket | Rhode Island |
| United States | TG Therapeutics Investigational Trial Site | Pensacola | Florida |
| United States | TG Therapeutics Investigational Trial Site | Philadelphia | Pennsylvania |
| United States | TG Therapeutics Investigational Trial Site | Pismo Beach | California |
| United States | TG Therapeutics Investigational Trial Site | Pleasanton | California |
| United States | TG Therapeutics Investigational Trial Site | Pompton Plains | New Jersey |
| United States | TG Therapeutics Investigational Trial Site | Portland | Oregon |
| United States | TG Therapeutics Investigational Trial Site | Portland | Oregon |
| United States | TG Therapeutics Investigational Trial Site | Raleigh | North Carolina |
| United States | TG Therapeutics Investigational Trial Site | Richmond | Virginia |
| United States | TG Therapeutics Investigational Trial Site | Saint Louis Park | Minnesota |
| United States | TG Therapeutics Investigational Trial Site | Saint Petersburg | Florida |
| United States | TG Therapeutics Investigational Trial Site | Salisbury | Maryland |
| United States | TG Therapeutics Investigational Trial Site | San Antonio | Texas |
| United States | TG Therapeutics Investigational Trial Site | Santa Barbara | California |
| United States | TG Therapeutics Investigational Trial Site | Seattle | Washington |
| United States | TG Therapeutics Investigational Trial Site | Sioux Falls | South Dakota |
| United States | TG Therapeutics Investigational Trial Site | Somerville | New Jersey |
| United States | TG Therapeutics Investigational Trial Site | Spokane | Washington |
| United States | TG Therapeutics Investigational Trial Site | Springfield | Massachusetts |
| United States | TG Therapeutics Investigational Trial Site | Springfield | Oregon |
| United States | TG Therapeutics Investigational Trial Site | Stamford | Connecticut |
| United States | TG Therapeutics Investigational Trial Site | Syracuse | New York |
| United States | TG Therapeutics Investigational Trial Site | Tucson | Arizona |
| United States | TG Therapeutics Investigational Trial Site | Tyler | Texas |
| United States | TG Therapeutics Investigational Trial Site | Urbana | Illinois |
| United States | TG Therapeutics Investigational Trial Site | Vancouver | Washington |
| United States | TG Therapeutics Investigational Trial Site | Watertown | South Dakota |
| United States | TG Therapeutics Investigational Trial Site | Webster | Texas |
| United States | TG Therapeutics Investigational Trial Site | West Palm Beach | Florida |
| United States | TG Therapeutics Investigational Trial Site | Westwood | Kansas |
| United States | TG Therapeutics Investigational Trial Site | Worcester | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| TG Therapeutics, Inc. |
United States, Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall Response Rate (ORR) | ORR: Percentage of participants with best overall response of partial response(PR) and complete response(CR). CR criteria: No evidence of new disease; Absolute lymphocyte count(ALC)<4x10^9/liter(L); Regression of all target nodal masses to =1.5 centimeters(cm) in longest diameter(LD); Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; Absolute neutrophil count(ANC)>1.5x10^9/L,platelets=100x10^9/L,hemoglobin (Hgb)=110 gram per liter(g/L). PR criteria: No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC<4x10^9/L or >=50% decrease from baseline in sum of products(SPD) of target nodal lesions; splenomegaly; hepatomegaly;>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; response in any 1:ANC>1.5x10^9/L,platelets>100x10^9/L,Hgb>110g/L or >=50% increase over baseline in any of these. | Up to 62 months | |
| Secondary | Complete Response (CR) Rate | The CR rate was defined as the percentage of participants who achieved CR. CR criteria: No evidence of new disease; ALC <4 x 10^9/L; Regression of all target nodal masses to normal size =1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC >1.5 x 10^9/L, platelets =100 x 10^9/L, Hgb =110 g/L. | Up to 62 months | |
| Secondary | Minimum Residual Disease (MRD) Negativity Rate | MRD negativity rate was defined as the percentage of participants who were MRD negative post-baseline. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow. | Up to 62 months | |
| Secondary | Progression-Free Survival (PFS) | PFS was defined as the time from the date of randomization until the date of first documentation of definitive disease progression (PD) or date of death from any cause, whichever occurs first. PD requires at least one of the following: New nodes >1.5 cm in the LD and >1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, =50% increase from the nadir in the sum of products of target lesions, =50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of =50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, >50% decrease from the highest on-study platelet count, >20 g/L decrease from the highest on-study Hgb. | From the randomization until the first documentation of PD or death whichever occurs first or up to 62 months | |
| Secondary | Duration of Response (DOR) | DOR:Interval from first documentation of CR/PR to first documentation of PD or death from any cause.CR:ALC<4x10^9/L;Regression to normal of target nodal masses,nodal non-target disease,and no detectable non-nodal,non-target disease;Normal spleen,liver size;Morphologically negative bone marrow,No lymphoid nodules;ANC>1.5x10^9/L,Platelets=100x10^9/L,Hgb=110 g/L.PR:Response in 2 or more:ALC<4x10^9/L,>=50% drop from baseline in ALC or SPD of target nodal lesions,Hepatosplenomegaly,>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;Response in 1 or more:ANC>1.5x10^9/L,Platelets>100x10^9/L,Hgb>110 g/L or >=50% increase over baseline in any.PD:Response in 1 or more:new nodes,Hepatosplenomegaly,unequivocal extra-nodal lesion;=50% increase from nadir in SPD of target lesions or LD of node/extra-nodal mass or Splenic/Hepatic size,Unequivocal increase in non-target disease,More aggressive histology;Drop of >50% in platelets/>20g/L in Hgb from highest on-study count. | From the first dose of study drug until the first documentation of PD or death whichever occurs first or up to 62 months | |
| Secondary | Time to Response (TTR) | TTR was defined as the interval from the randomization to the first documentation of CR or PR. CR criteria: No evidence of new disease; ALC <4 x 10^9/L; Regression of all target nodal masses to normal size =1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC >1.5 x 10^9/L, platelets =100 x 10^9/L, Hgb =110 g/L. PR criteria: No evidence of new disease; Response in 2 of following when abnormal at baseline: ALC<4 x 10^9/L or >=50% decrease from baseline in SPD of target nodal lesions; splenomegaly; hepatomegaly; >=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; and Response in 1 of the following: ANC>1.5 x 10^9/L, platelets>100 x 10^9/L, Hgb>110 g/L or >=50% increase over baseline in any of these. | From the randomization up to 62 months | |
| Secondary | Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) | An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related. | From the first dose up to 30 days after the last dose of study drug (up to 57.3 months) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
| Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
| Active, not recruiting |
NCT04240704 -
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
|
Phase 1 | |
| Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03280160 -
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
|
Phase 2 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
| Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
| Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
| Recruiting |
NCT05417165 -
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
| Recruiting |
NCT04028531 -
Understanding Chronic Lymphocytic Leukemia
|
||
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
| Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
| Recruiting |
NCT04679012 -
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
|
Phase 2 | |
| Recruiting |
NCT05405309 -
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05023980 -
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
| Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
| Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|